{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:23:04Z","timestamp":1773663784946,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Netherlands Ministry of Health, Welfare and Sport"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive meningococcal B disease (IMD-B) causes morbidity and mortality among infants and adolescents in the Netherlands. While multiple vaccines against IMD-B are licensed by the European Medicines Agency, none of them is currently part of the Dutch National Immunization Program (NIP). We evaluated the clinical impact and cost-effectiveness of different IMD-B vaccination strategies for Dutch infants and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a static, single-cohort Markov model to estimate the lifetime number of IMD-B cases and deaths prevented, as well as the incremental cost-effectiveness ratio (ICER), of vaccinating infants with 4CMenB (age 0; 2\u2009+\u20091 schedule) or adolescents with 4CMenB, MenB-fHBp, or MenABCWY\u2009+\u2009MenB-fHBp (age 15; 1\u2009+\u20091 schedule), compared with no IMD-B vaccination. The analysis adopted a societal perspective, including costs and quality-adjusted life years (QALYs) related to vaccination, adverse events, acute IMD-B, long-term sequelae, productivity losses of patients and caregivers, special education needs, and out-of-pocket expenses for patients and their families. We also conducted a threshold analysis for the incidence of IMD-B and a systematic uncertainty assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For infants, the use of 4CMenB would prevent 11.14 IMD-B cases and 0.85 IMD-B-related deaths in one birth cohort of 166,073 infants over a lifetime. For adolescents, IMD-B vaccination would prevent 7.24\u20138.57 cases and 0.25\u20130.29 deaths in a single cohort of 197,782 adolescents, depending on which vaccine is used. The ICER was \u20ac594,056\/QALY for 4CMenB in infants, while for adolescents the ICER ranged between \u20ac717,287\/QALY and \u20ac890,023\/QALY, depending on the vaccine type used. These ICERs exceed the commonly used cost-effectiveness thresholds (\u20ac20,000 to \u20ac80,000\/QALY gained) in the Netherlands, rendering vaccination not cost-effective. This outcome proved robust in deterministic and probabilistic sensitivity analyses, as well as in scenario analyses. The threshold analysis demonstrated that IMD-B vaccination may only become cost-effective at a \u20ac80,000\/QALY threshold with more than a sixfold increase in incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The modelled IMD-B vaccination programs resulted in the prevention of limited morbidity and mortality at a high financial burden. The inclusion of any of the evaluated vaccines in the Dutch NIP for infants or adolescents is not cost-effective in any target group at conventional Dutch cost-effectiveness thresholds given current IMD-B incidence levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-026-04651-z","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:34:33Z","timestamp":1770719673000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact and cost-effectiveness of vaccinating infants and adolescents against invasive meningococcal B disease in the Netherlands"],"prefix":"10.1186","volume":"24","author":[{"given":"Thomas","family":"Otten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjam","family":"Knol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lard Montesano","family":"Montessori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke","family":"Steens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"4651_CR1","unstructured":"van Roon AL, SL; de Melker HE. The National Immunisation Programme in the Netherlands. RIVM; 2024.\u00a0https:\/\/www.rivm.nl\/publicaties\/national-immunisation-programme-in-netherlands-surveillance-and-developments-in-2024."},{"key":"4651_CR2","doi-asserted-by":"crossref","unstructured":"Middeldorp M, Steens A, Lagerweij G, van Sorge NM, Freudenburg-de Graaf W, E AMS, et al. The burden of invasive meningococcal disease in the Netherlands, 2011\u20132020. Vaccine. 2023;41(16):2664\u201370.","DOI":"10.1016\/j.vaccine.2023.03.017"},{"key":"4651_CR3","unstructured":"Knol MJ MML, Steens L, de Melker H, Otten T, Visser L, Visser M, Mariman R, Rots N, Wallinga J, de Boer P, van Sorge N. Meningococcal disease serogroup B. RIVM; 2025.\u00a0https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2017-0031.pdf."},{"key":"4651_CR4","unstructured":"EMA. Bexsero | meningococcal group B Vaccine (rDNA, component, adsorbed). 2024."},{"key":"4651_CR5","unstructured":"EMA. Trumenba | meningococcal group b vaccine (recombinant, adsorbed). 2025."},{"key":"4651_CR6","unstructured":"FDA. Penbraya 2024 [updated 11\/21\/20247\u20133\u20132025]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/penbraya."},{"key":"4651_CR7","unstructured":"GlaxoSmithKline. Penmenvy, GSK\u2019s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY. 2025. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy\/. Updated 15\/02\/2025."},{"key":"4651_CR8","unstructured":"EMA. Penbraya (meningococcal groups A, C, W, Y conjugate and group B vaccine (recombinant, adsorbed)). 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/penbraya. Updated 05\/02\/2025."},{"key":"4651_CR9","unstructured":"Gezondheidsraad. Vaccinatie tegen meningokokken B: update. Den Haag: Gezondheidsraad; 2022. Available from: https:\/\/www.gezondheidsraad.nl\/site\/binaries\/site-content\/collections\/documents\/2022\/10\/12\/advies-vaccinatie-tegen-meningokokken-b-update\/advies-Vaccinatie-tegen-MenB_update.pdf."},{"issue":"5","key":"4651_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.4161\/hv.23888","volume":"9","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother. 2013;9(5):1129\u201338.","journal-title":"Hum Vaccin Immunother"},{"key":"4651_CR11","unstructured":"RIVM. Meningokokken B-vaccinatie factsheet. 2025. Available from: https:\/\/lci.rivm.nl\/richtlijnen\/meningokokken-b-vaccinatie."},{"issue":"1","key":"4651_CR12","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1186\/s12879-021-06906-x","volume":"21","author":"L Argante","year":"2021","unstructured":"Argante L, Abbing-Karahagopian V, Vadivelu K, Rappuoli R, Medini D. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model. BMC Infect Dis. 2021;21(1):1244.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"4651_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jinf.2023.05.021","volume":"87","author":"B Wang","year":"2023","unstructured":"Wang B, Giles L, Andraweera P, McMillan M, Almond S, Beazley R, et al. 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. J Infect. 2023;87(2):95\u2013102.","journal-title":"J Infect"},{"issue":"5","key":"4651_CR14","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2206433","volume":"388","author":"J Castilla","year":"2023","unstructured":"Castilla J, Garcia Cenoz M, Abad R, Sanchez-Cambronero L, Lorusso N, Izquierdo C, et al. Effectiveness of a Meningococcal Group B vaccine (4CMenB) in Children. N Engl J Med. 2023;388(5):427\u201338.","journal-title":"N Engl J Med"},{"key":"4651_CR15","unstructured":"Seedat J, Winkler M. STIKO: Standardimpfung von S\u00e4uglingen gegen Meningokokken der Serogruppe B. Berlin: Robert Koch-Institut; 2024. Report No.: 2569\u20135266."},{"issue":"1","key":"4651_CR16","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/14760584.2023.2222015","volume":"22","author":"GS Marshall","year":"2023","unstructured":"Marshall GS, Abbing-Karahagopian V, Marshall HS, Cenci S, Conway JH, Occhipinti E, et al. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Expert Rev Vaccines. 2023;22(1):530\u201344.","journal-title":"Expert Rev Vaccines"},{"issue":"8","key":"4651_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/cid\/civ506","volume":"61","author":"SP Stoof","year":"2015","unstructured":"Stoof SP, Rodenburg GD, Knol MJ, Rumke LW, Bovenkerk S, Berbers GA, et al. Disease burden of invasive meningococcal disease in the Netherlands between June 1999 and June 2011: a subjective role for serogroup and clonal complex. Clin Infect Dis. 2015;61(8):1281\u201392.","journal-title":"Clin Infect Dis"},{"key":"4651_CR18","unstructured":"EMA. Trumenba meningococcal group b vaccine (recombinant, adsorbed). 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trumenba."},{"key":"4651_CR19","unstructured":"CBS. Bevolkingsprognose 2023\u20132070: minder geboorten, meer migratie Online - cbs.nl; 2023. Available from: https:\/\/www.cbs.nl\/nl-nl\/longread\/statistische-trends\/2023\/bevolkingsprognose-2023-2070-minder-geboorten-meer-migratie#:~:text=Dit%20artikel%20beschrijft%20de%20uitkomsten%20en%20veronderstellingen%20van,voor%20de%20bevolking%20naar%20leeftijd%2C%20geslacht%20en%20herkomst. Updated 19.02.2025."},{"issue":"4","key":"4651_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","volume":"382","author":"HS Marshall","year":"2020","unstructured":"Marshall HS, McMillan M, Koehler AP, Lawrence A, Sullivan TR, MacLennan JM, et al. Meningococcal B vaccine and meningococcal carriage in adolescents in Australia. N Engl J Med. 2020;382(4):318\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"4651_CR21","doi-asserted-by":"publisher","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","volume":"73","author":"M McMillan","year":"2021","unstructured":"McMillan M, Chandrakumar A, Wang HLR, Clarke M, Sullivan TR, Andrews RM, et al. Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal neisseria meningitidis carriage: a systematic Review And Meta-Analysis. Clin Infect Dis. 2021;73(3):e609\u201319.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4651_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jinf.2024.01.002","volume":"88","author":"M McMillan","year":"2024","unstructured":"McMillan M, Mohammed H, Bednarz J, Leong LEX, Lawrence A, Sullivan TR, et al. Longitudinal study of meningococcal carriage in adolescents and young adults in South Australia 2017\u20132020. J Infect. 2024;88(2):149\u201357.","journal-title":"J Infect"},{"key":"4651_CR23","unstructured":"ZIN. Guideline for economic evaluations in healthcare. National Health Care Institute; 2024. https:\/\/english.zorginstituutnederland.nl\/documents\/2024\/01\/16\/guideline-for-economic-evaluations-in-healthcare."},{"key":"4651_CR24","unstructured":"van Lier EA, Hament J-M, Knijff M, Westra M, Giesbers M, Drijfhout IH, et al. Vaccinatiegraad Rijksvaccinatieprogramma Nederland. Rijksinstituut voor Volksgezondheid en Milieu; 2024.\u00a0https:\/\/www.rivm.nl\/bibliotheek\/rapporten\/2024-0044.pdf."},{"issue":"8","key":"4651_CR25","doi-asserted-by":"publisher","first-page":"e2329678","DOI":"10.1001\/jamanetworkopen.2023.29678","volume":"6","author":"L Lodi","year":"2023","unstructured":"Lodi L, Barbati F, Amicizia D, Baldo V, Barbui AM, Bondi A, et al. Four-component recombinant protein-based vaccine effectiveness against serogroup B meningococcal disease in Italy. JAMA Netw Open. 2023;6(8):e2329678.","journal-title":"JAMA Netw Open"},{"issue":"32","key":"4651_CR26","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.1016\/j.vaccine.2021.06.005","volume":"39","author":"L Ostergaard","year":"2021","unstructured":"Ostergaard L, Vesikari T, Senders SD, Flodmark CE, Kosina P, Jiang HQ, et al. Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months. Vaccine. 2021;39(32):4545\u201354.","journal-title":"Vaccine"},{"issue":"29","key":"4651_CR27","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","volume":"34","author":"H Christensen","year":"2016","unstructured":"Christensen H, Irving T, Koch J, Trotter CL, Ultsch B, Weidemann F, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero((R)) to reduce meningococcal group B disease in Germany. Vaccine. 2016;34(29):3412\u20139.","journal-title":"Vaccine"},{"key":"4651_CR28","unstructured":"Medicijnkosten.nl. BEXSERO INJSUSP WWSP 0,5ML. Medicijnkosten.nl. Available from: https:\/\/www.medicijnkosten.nl\/medicijn?artikel=BEXSERO+INJSUSP+WWSP+0%2C5ML+%2B+TOEBEH&id=91325ce387bed983e3ff773cf64f1c68."},{"key":"4651_CR29","unstructured":"Medicijnkosten.nl. TRUMENBA INJSUSP WWSP 0,5ML. Medicijnkosten.nl. Available from:\u00a0https:\/\/www.medicijnkosten.nl\/medicijn?artikel=TRUMENBA+INJSUSP+WWSP+0%2C5ML&id=30b24fa2c904a77ee9ad3174dcbf4f1f."},{"issue":"4","key":"4651_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.vaccine.2017.11.076","volume":"36","author":"S Harcourt","year":"2018","unstructured":"Harcourt S, Morbey RA, Bates C, Carter H, Ladhani SN, de Lusignan S, et al. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine. 2018;36(4):565\u201371.","journal-title":"Vaccine"},{"key":"4651_CR31","unstructured":"Medicijnkosten.nl. NIMENRIX INJPDR FLACON + SOLVENS IN WWSP. Medicijnkosten.nl. Available from: https:\/\/www.medicijnkosten.nl\/medicijn?artikel=NIMENRIX+INJPDR+FLACON+%2B+SOLVENS+IN+WWSP&id=6263e1ce844c79b5df81967601811473."},{"issue":"5","key":"4651_CR32","doi-asserted-by":"publisher","first-page":"e0177082","DOI":"10.1371\/journal.pone.0177082","volume":"12","author":"ITR Kennedy","year":"2017","unstructured":"Kennedy ITR, van Hoek AJ, Ribeiro S, Christensen H, Edmunds WJ, Ramsay ME, et al. Short-term changes in the health state of children with group B meningococcal disease: a prospective, national cohort study. PLoS ONE. 2017;12(5):e0177082.","journal-title":"PLoS ONE"},{"issue":"4","key":"4651_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.vaccine.2004.06.019","volume":"23","author":"R Welte","year":"2004","unstructured":"Welte R, van den Dobbelsteen G, Bos JM, de Melker H, van Alphen L, Spanjaard L, et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in the Netherlands and its impact on decision-making. Vaccine. 2004;23(4):470\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"4651_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-effectiveness of 4CMenB infant vaccination in England: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91\u2013104.","journal-title":"Value Health"},{"issue":"3","key":"4651_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40121-023-00903-0","volume":"13","author":"F Zeevat","year":"2024","unstructured":"Zeevat F, Simons JJM, Westra TA, Wilschut JC, van Sorge NM, Boersma C, et al. Cost of illness analysis of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in the Netherlands-a holistic approach. Infect Dis Ther. 2024;13(3):481\u201399.","journal-title":"Infect Dis Ther"},{"issue":"9","key":"4651_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","volume":"11","author":"RM Viner","year":"2012","unstructured":"Viner RM, Booy R, Johnson H, Edmunds WJ, Hudson L, Bedford H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol. 2012;11(9):774\u201383.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4651_CR37","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","volume":"32","author":"JA Bettinger","year":"2013","unstructured":"Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"4651_CR38","unstructured":"Statista. Average annual working hours in the Netherlands by age. Statista; 2022. Available from: https:\/\/www.statista.com\/statistics\/538657\/average-annual-working-hours-in-the-netherlands-by-age\/. Updated 2025\u201302\u201319."},{"key":"4651_CR39","unstructured":"Statista. Average monthly wage in the Netherlands by age. Statista; 2022. Available from: https:\/\/www.statista.com\/statistics\/538025\/average-monthly-wage-in-the-netherlands-by-age\/. Updated 2025\u201302\u201319."},{"key":"4651_CR40","unstructured":"CBS. Dashboard Arbeidsmarkt - Arbeidsparticipatie naar leeftijd en geslacht. Centraal Bureau voor de Statistiek; 2023. Available from: https:\/\/www.cbs.nl\/nl-nl\/visualisaties\/dashboard-arbeidsmarkt\/werkenden\/arbeidsparticipatie-naar-leeftijd-en-geslacht. Updated 2025\u201302\u201319."},{"key":"4651_CR41","unstructured":"Polder JvE J, Kahlman J, Knies S, Mierau J, Vermeulen W, de Wit A, Wouterse B, Rotteveel A.\u00a0PREVENTIE OP WAARDE SCHATTEN ADVIES TECHNISCHE WERKGROEP KOSTEN EN BATEN VAN PREVENTIE. 2023."},{"issue":"1","key":"4651_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40121-021-00573-w","volume":"11","author":"S Scholz","year":"2022","unstructured":"Scholz S, Schwarz M, Beck E, Meszaros K, Schneider M, Ultsch B, et al. Public health impact and cost-effectiveness analysis of routine infant 4CMenB vaccination in Germany to prevent serogroup B invasive meningococcal disease. Infect Dis Ther. 2022;11(1):367\u201387.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"4651_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40273-019-00855-9","volume":"38","author":"SE Grimm","year":"2020","unstructured":"Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Knies S, Grutters J, et al. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) tool for assessing uncertainties in health economic decision models. Pharmacoeconomics. 2020;38(2):205\u201316.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"4651_CR44","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","volume":"37","author":"NC Buyukkaramikli","year":"2019","unstructured":"Buyukkaramikli NC, van Rutten- Molken M, Severens JL, Al M. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391\u2013408.","journal-title":"Pharmacoeconomics"},{"key":"4651_CR45","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.43.2300131","author":"D Martinelli","year":"2023","unstructured":"Martinelli D, Quattrone F, Fortunato F, Di Maggio E, Filia A, Rota MC, et al. Role of the National Immunisation Technical Advisory Groups in 13 European countries in the decision-making process on vaccine recommendations. Euro Surveill. 2023. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.43.2300131.","journal-title":"Euro Surveill"},{"issue":"11","key":"4651_CR46","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s40121-024-01026-w","volume":"13","author":"GS Marshall","year":"2024","unstructured":"Marshall GS, McCormick ZL, Johns JS, Verduzco-Gutierrez M, Herrera-Restrepo O, Harrison LH. Understanding the sequelae of invasive meningococcal disease in the United States. Infect Dis Ther. 2024;13(11):2213\u201320.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"4651_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3201\/eid2503.181574","volume":"25","author":"HM Soeters","year":"2019","unstructured":"Soeters HM, McNamara LA, Blain AE, Whaley M, MacNeil JR, Hariri S, et al. University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013\u20132018. Emerg Infect Dis. 2019;25(3):434\u201340.","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"4651_CR48","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3201\/eid1211.060682","volume":"12","author":"J Elias","year":"2006","unstructured":"Elias J, Harmsen D, Claus H, Hellenbrand W, Frosch M, Vogel U. Spatiotemporal analysis of invasive meningococcal disease, Germany. Emerg Infect Dis. 2006;12(11):1689\u201395.","journal-title":"Emerg Infect Dis"},{"key":"4651_CR49","unstructured":"Gezondheidsraad. Covid-19-vaccinatie in 2025 [27 maart 2025]. 2025. Available from: https:\/\/www.gezondheidsraad.nl\/site\/binaries\/site-content\/collections\/documents\/2025\/03\/27\/advies-covid-19-vaccinatie-in-2025\/COVID-19-vaccinatie-in-2025-advies.pdf."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04651-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04651-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04651-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:39:21Z","timestamp":1773661161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04651-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4651"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04651-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the study design, this article did not require ethical approval.As no participants were involved, this article did not require consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have given their consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}